Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with ...
DEVON, Pa., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it …